Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Head & Neck 3Genitourinary 3Breast 3Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Endocrine 1CNS 1

Conditions

Recurrence 1Mesothelioma 1

Interventions

pembrolizumab 26Cisplatin 15Pemetrexed 14Paclitaxel 14Carboplatin 14Nivolumab 10Cyclophosphamide 10Docetaxel 8atezolizumab 7Injections 7Melphalan 6tislelizumab 5olaparib 5Gemcitabine 5Filgrastim 5durvalumab 4aldesleukin 4Leucovorin 4Irinotecan 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bevacizumab 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3defactinib 3adavosertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × vandetanib × Other solid neoplasm × Clear all
NCT00597116 2016-10-10

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Sanofi

Phase 2 Terminated
25 enrolled 8 charts
Other solid neoplasmThoracic

Mesothelioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡